Additional Information

Description

Ilaris 150 mg/mL vial is a monoclonal antibody formulation containing canakinumab, designed for subcutaneous administration. It is an interleukin-1 beta (IL-1ß) inhibitor used in the treatment of autoinflammatory conditions. By selectively binding to IL-1ß, it prevents inflammatory signaling, reducing symptoms associated with excessive immune activation. The medication is indicated for periodic fever syndromes, including cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

In systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD), Ilaris reduces systemic inflammation, fever, and joint manifestations by suppressing IL-1ß activity. It provides sustained symptom control with a single subcutaneous dose administered every four to eight weeks, depending on the condition.

Ilaris is supplied as a lyophilized powder in a single-use vial requiring reconstitution before administration. It should be prepared using sterile techniques and injected subcutaneously by a healthcare professional. Patients should be monitored for potential hypersensitivity reactions, infections, and neutropenia.